Documente Academic
Documente Profesional
Documente Cultură
net/publication/26250635
CITATIONS READS
35 2,881
3 authors, including:
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Jens H Henriksen on 24 November 2014.
REVIEW ARTICLE
Abstract
Ascites is a classic complication of advanced cirrhosis and it often marks the first sign of hepatic decompensation. Ascites
occurs in more than 50% of patients with cirrhosis, worsens the course of the disease, and reduces survival substantially.
Portal hypertension, splanchnic vasodilatation, liver insufficiency, and cardiovascular dysfunction are major pathophysio-
logical hallmarks. Modern treatment of ascites is based on this recognition and includes modest salt restriction and stepwise
diuretic therapy with spironolactone and loop-diuretics. Tense and refractory ascites should be treated with large volume
paracentesis followed by plasma volume expansion or transjugular intrahepatic portosystemic shunt. Ascites complicated by
spontaneous bacterial peritonitis requires adequate treatment with antibiotics. New potential treatment strategies include
the use of vasopressin V2-receptor antagonists and vasoconstrictors. Since formation of ascites is associated with a poor
prognosis, and treatment of fluid retention does not substantially improve survival, such patients should always be
For personal use only.
Correspondence: Søren Møller, MD, DMSc, Associate Professor, Department of Clinical Physiology 239, Hvidovre Hospital, DK-2650 Hvidovre, Denmark.
Tel: 45 3632 3568. Fax: 45 3632 3750. E-mail: soeren.moeller@hvh.regionh.dk
of ascites are portal and sinusoidal hypertension, venous inflow together with the development of
arterial vasodilatation, and neurohumoral activation, portosystemic collaterals determine the height of
all leading to sodium and water retention [10,11]. the portal pressure. Factors that determine hepatic
According to the peripheral arterial vasodilatation vascular resistance include both structural and
theory, development of systemic and splanchnic dynamic components [16]. Among the structural
vasodilatation results in a decrease in the effective components are fibrosis and regeneration nodules.
arterial blood volume and a hyperdynamic circula- Dynamic structures include hepatic stellate cells,
tion [12]. This theory has lately been modified into myofibroblasts, and other cells with contractile
what has been termed ‘‘the forward theory of ascites properties. A preferential sinusoidal constriction in
For personal use only.
formation’’ (Figure 1) which combines arterial the liver seems to be attributed to a defective nitric
oxide (NO) production but also to endogenous
underfilling with a forward increase in splanchnic
vasoconstrictors like endothelin-1 (ET-1), angioten-
capillary pressure and filtration with increased
sin II, catecholamines, and leukotrienes may all
lymph formation [3].
increase the hepatic sinusoidal resistance [1618].
The haemodynamic imbalance with a predominant
sinusoidal constriction contributes significantly to
the development of portal hypertension and thereby
Cirrhosis and liver
dysfunction is an important target for treatment.
Moreover, the formation of ascites depends on the
Portal
hypertension balance between the increased local transvascular
TIPS
filtration and augmented lymph drainage [2]. Thus,
Increased splanchnic β-adrenergic Increased production
the amount of ascitic fluid produced is governed by
capillary pressure blockers of vasodilators
increased transsinusoidal filtration of protein and
fluid and by accelerated transperitoneal hydrostatic
Increased lymph
Splanchnicarteriolar and oncotic dynamics. However, in contrast to
formation vasodilatation earlier assumptions, the decreased plasma oncotic
pressure may be of minor importance for the
Paracentesis
generation of ascites and low plasma concentrations
Ascites plasma
Volume V1 receptor Central hypovolaemia of albumin have little influence on the rate of ascites
expansion agonists Arterial hypotension formation (Figure 2) [2,19,20]. In this context, the
α-1agonist Deloadingof arterial
baroreceptors
increased hydrostatic pressure in the sinusoids and
Plasma volume intestinal capillaries is critical, and ascites rarely
expansion
β-adrenergic
develops in patients with a hepatic venous pressure
Activation of
blockers SNS gradient below 12 mmHg [21].
Activation of Aldosterone
Loop- Sodium and water RAAS antagonists
diuretics retention
Activation of
vasopressin
V2 receptor
antagonists
Pathophysiology of arterial vasodilatation and
neurohumoral activation
Figure 1. Pathophysiology of the development of ascites in
cirrhosis and potential targets for treatment. SNS sympathetic The pathophysiological coupling between early portal
nervous system; RAAS renin-angiotensin-aldosterone system; hypertension and the development of the systemic
AVP arginine vasopressin. and splanchnic vasodilatation and the hyperdynamic
904 S. Møller et al.
WHVP = 20 mmHg FHVP = 2 mmHg
Hepatocytes
Space of Disse
with stellate cells
Sinusoid lined by
endothelial cells
Figure 2. Hydrostatic pressures and transperitoneal fluid dynamics in cirrhosis: An increased hepatic venous pressure gradient (HVPG)
generates increased transsinusoidal fluid filtration with an overall increased hepatosplanchnic lymph flow of 1025 l/24 h. As long as the
transsinusoidal filtration keeps pace with lymphatic drainage, no surplus protein-rich fluid will spill over into the peritoneal cavity. When
filtration exceeds the lymphatic drainage, protein-rich fluid will accumulate in the peritoneal cavity as ascites. However, this spillover
fraction (0.5 l/24 h) is relatively small compared to the overall transsinusoidal filtration and lymphatic drainage. WHVPwedged hepatic
venous pressure; FHVPfree hepatic venous pressure.
For personal use only.
syndrome is still obscure. It may be brought about primarily synthesized in the systemic vascular
either by overproduction of circulating vasodilators endothelium by NO synthase [25,26]. In portal
induced by shear stress in the splanchnic circulation or hypertension, there seems to be a diminished release
by direct neurohumoral signals from the liver to the of NO from sinusoidal endothelial cells in the
brain [18,22]. Several findings indicate that the cirrhotic liver, whereas in the systemic circulation
splanchnic vasodilatation precedes renal sodium and there is evidence of an up-regulation of the NO
water retention [23]. In experimental as well as in synthesis [27]. Calcitonin gene-related peptide
human portal hypertension, splanchnic vasodilata- (CGRP) and adrenomedulin are potent vasodilatat-
tion leads to reduced systemic vascular resistance, ing neuropeptides, which have been found increased
decreased effective blood volume, and a reduction in especially in patients with ascites and the hepator-
arterial blood pressure with activation of potent enal syndrome (HRS) [18,23]. The increase in
vasoconstricting systems such as the sympathetic
circulating vasoactive substances is mainly due to
nervous system (SNS), the renin-angiotensin-aldos-
increased production and, to a lesser extent, to a
terone system (RAAS), and non-osmotic release of
decrease in hepatic clearance [28]. It is likely that
vasopressin [3,11,18]. The haemodynamic conse-
these peptides play a role as neurotransmitters, both
quences of the development of a hyperdynamic
in the initiation of the haemodynamic changes and in
circulation with an increased heart rate and cardiac
output have previously been described as a mediator the perpetuation of the hyperdynamic circulation
of the effective blood volume, and underfilling of the and the formation of ascites. Systemic vasodilatation
arterial circulation occurs in these patients as a result has also been related to resistance to pressor
of diminished systemic vascular resistance [12]. substances, such as noradrenaline, angiotensin II,
However, at a much later stage of the disease, under- and vasopressin. An impaired response to these
filling of the arterial circulation may also occur vasoconstrictors is most likely related to changes in
secondary to a reduction of the increased cardiac receptor affinity, down-regulation of receptors, and
output, as described in patients with renal failure and to post-receptor defects related to increased NO
SBP [24]. expression [18,29,30]. Recently, alterations in arter-
NO is among the vasodilators that have been ial and total vascular compliance have also been
implicated in the systemic vasodilatation, and is considered [31,32].
Treatment of ascites 905
Although the pathophysiology and the role of decreased urinary sodium excretion, and the absence
arterial vasodilatation are complex, there is definite of ascites in this phase can be achieved by reducing
experimental and clinical evidence to show that it the dietary intake of sodium. At this stage there is
precedes the counter-regulatory neurohumoral acti- only activation of the RAAS and SNS in some
vation and the renal sodium and water retention in patients, and the GFR and RBF may be normal
cirrhosis. [40]. In phase 3, sodium excretion is often below
10 mmol/day and there is immense activation of the
RAAS and SNS, but the RBF and GFR are still
Renal dysfunction normal or low normal [41,42]. The arterial blood
In the early phases of cirrhotic portal hypertension, pressure is often low or low normal, despite activa-
the renal sodium excretion capacity is impaired, with tion of RAAS and SNS, and therefore these patients
reduced natriuretic response to acute administration are highly susceptible to the hypotensive effects of
of sodium chloride or to changes in posture [33,34]. angiotensin-converting enzyme (ACE) inhibitors,
These early events are seen before the development angiotensin II receptor inhibitors, and V1-vasopres-
of ascites, but in most of the patients they represent sin antagonist [8]. Phases 4 and 5 ascites denote the
the initiation of a more pronounced renal dysfunc- development of the HRS type 2 and type 1,
Scand J Gastroenterol Downloaded from informahealthcare.com by HINARI on 02/13/11
tion. This includes progressively increased sodium respectively. Type-2 HRS is characterized by mod-
and water reabsorption and decreases in renal erate renal failure with a slow progressive course and
perfusion and the glomerular filtration rate (GFR) it is typically associated with refractory ascites. Type-
often in parallel with reduced liver function [35]. In 1 HRS is characterized by a rapid decrease in renal
healthy individuals on a normal intake of sodium function which is often precipitated by SBP [43].
chloride, the free water clearance approximates The new diagnostic criteria for HRS according to
10 ml/min [36]. In particular decompensated cir- The International Club of Ascites are presented in
rhotic patients, the free water clearance is often less Table III [43].
than 1 ml/min, equivalent to an intake of 1.5 l/day
For personal use only.
Term Phase Sodium and water retention Activated RAAS and SNS Impaired RBF and GFR
Abbreviations: RAASrenin-angiotensin-aldosterone system; SNSsympathetic nervous system; RBFrenal blood flow; GFR
glomerular filtration rate; HRShepatorenal syndrome.
Modified from Arroyo et al. [3].
906 S. Møller et al.
Table III. New diagnostic criteria of the hepatorenal syndrome
Medical treatment. A strategy for the treatment of
(HRS) according to The International Club of Ascites [43].
ascites is presented in Table IV. Diuretics have been
used for the treatment of fluid retention for more than
Cirrhosis with ascites.
Serum creatinine 133 mmol/l (1.5 mg/dl) 60 years. The diuretic treatment of ascites should be
No improvement of serum creatinine (decrease to a level of initiated with an aldosterone antagonist that acts
5133 mmol/l) after at least 2 days with diuretic withdrawal and mainly on the distal tubules in order to increase
volume expansion with albumin. The recommended dose of natriuresis, since, if furosemide is administered alone,
albumin is 1 g/kg body weight per day up to a maximum of
100 g/day
its natriuretic effects on the loop of Henle will be
Absence of shock counteracted by sodium reabsorbed in the distal
No current or recent treatment with nephrotoxic drugs tubules, because of activation of aldosterone. The
Absence of parenchymal kidney disease as indicated by initial prescription in mild to moderate ascites should
proteinuria 500 mg/day, microhaematuria (50 red
be 100 mg/day, a dose that can be gradually increased
blood cells per high-power field) and/or abnormal renal
ultrasonography up to 400 mg/day [3,4]. But, to avoid hyperkalaemia,
it is often necessary to give a loop diuretic supplement
before the full aldosterone antagonist dose. The full
effect of diuretic treatment is normally seen after 35
Scand J Gastroenterol Downloaded from informahealthcare.com by HINARI on 02/13/11
amylase should be measured on clinical suspicion of days. Body-weight should be checked daily and serum
pancreatic disease. Analyses of cytology should be sodium, potassium, and creatinine concentrations
carried if malignancy is suspected [45]. monitored. A daily weight loss of no more than 500
800 g is recommended to prevent intravascular vo-
Treatment of non-complicated ascites lume depletion [1]. In the case of massive peripheral
oedema, higher weight losses can be accepted. When
Para-medical treatment. Previous studies have shown this is insufficient, a loop diuretic should be added,
that the supine position ameliorates the RBF and usually furosemide, as it may induce marked diuresis
GFR and improves sodium and water excretion [46]. and natriuresis. The initial recommended dose is 40
For personal use only.
A less activated RAAS and SNS and a more mg/day and can be increased to 160 mg/day with a
favourable diuretic response in the supine patient stepwise increase every 23 days [4]. Additional
have led to the assumption that bedrest would diuresis can sometimes be achieved with the supple-
benefit the treatment of ascites. However, severe mentation of other diuretics such as amiloride or a
side effects of prolonged bedrest, for example an thiazide, but side effects are common. The main
increased risk of thromboembolic complications, purpose of the treatment is to keep the patient free
decalcification of the bones, and muscular atrophy, of ascites. When the ascites has been resolved,
imply that bedrest in general cannot be recom-
mended for the treatment of ascites [20]. Table IV. Suggestions for a progressive strategy in the treatment
Reduced salt intake will counteract the sodium of sodium and fluid retention and renal complications in cirrhosis.
imbalance in patients with fluid retention and may
create a negative sodium balance in some of the Clinical Treatment
patients; therefore a low salt diet should be part of condition
the basic treatment of ascites. However, a rigorous
Pre-ascitic No treatment
low salt diet is usually unacceptable to the patient cirrhosis Modest salt restriction (80120 mmol/day)
and thus a no-salt-added diet of 80120 mmol NaCl
per day is recommended. In patients with dilutional Mild ascites Salt restriction
hyponatraemia in particular, water restriction (1.0 Stepwise spironolactone (100400 mg/day)
1.5 l/day) has been used, but the effectiveness of this Moderatetense Salt restriction
ascites Spironolactone
treatment to increase the serum sodium concentra- Stepwise furosemide (40160 mg/day)
tion more than 5 mmol/l is limited and ranges from Refractory Large volume paracentesis and plasma volume
0% to 26% [47]. Moreover, water restriction has a ascites substitution and diuretics
limited effect on improving serum sodium, because TIPS
Hyponatraemia Serum sodiumB125 mmol/l: diuretics
the daily fluid intake cannot be reduced to less than
discontinued
one litre per day, which is insufficient to ensure a Serum sodiumB120 mmol/l: plasma volume
negative fluid balance [48]. Water restriction should expansion
be reserved only for patients who are clinically Hyper/euvolaemia: modest water restriction
hypervolaemic with severe hyponatraemia and de- Experimental vasopressin V2 receptor
antagonists
creased free water clearance. Thus, for practical
purposes, water can only be restricted in very few Abbreviation: TIPStransjugular intrahepatic portosystemic
(if any) patients. shunt.
Treatment of ascites 907
Table V. Definition of and diagnostic criteria for refractory ascites
ications, such as encephalopathy and hyponatraemia
in cirrhosis according to a consensus report from the International
Club of Ascites [4]. [4]. The response to diuretics and the salt diet should
be validated only in stable patients without bleeding or
infection, since such conditions affect the ability to
Diuretic-resistant ascites excrete salt and water.
Ascites that cannot be mobilized or the early recurrence of
which cannot be prevented, because of a lack of response to Ascites recurs in as much as 90% of patients
sodium restriction and diuretic treatment particularly in those with post-sinusoidal alcoholic
Diuretic-intractable ascites
cirrhosis after therapeutic paracentesis, and supple-
Ascites that cannot be mobilized or the early recurrence of mentation with a minimum dose of diuretics is
which cannot be prevented, because of the development of therefore essential [49]. Therapeutic paracentesis
diuretic-induced complications that preclude the use of an should be done in a single session and should always
effective diuretic dose be combined with plasma volume expansion. The
Conditions intra-abdominal, right atrial, and pulmonary capil-
1. Treatment duration: Patients must be on intensive diuretic lary wedge pressures decrease after large volume
therapy (spironolactone 400 mg/day and furosemide 160 mg/
paracentesis [31]. Cardiac output increases after 23
day) for at least 1 week and a salt-restricted diet of less than
h and the mean arterial blood pressure decreases by
Scand J Gastroenterol Downloaded from informahealthcare.com by HINARI on 02/13/11
24 patients [64]. PICD is an example of a complica- of reduced excretion of AQP2 [72,73]. Clinical use
tion attributable to further vasodilatation and reduc- of V2-receptor antagonists, known as the vaptans,
tion in effective blood volume, which can be may prove to be effective in the treatment of
prevented by specific volume support and vasocon- dilutional hyponatraemia. Up to the present time,
striction. The use of specific vasoconstrictors such as data on the long-term effects are needed but
midodrine or terlipressin may potentially play a role randomized trials are currently in progress [47,74].
in the future strategy of treatment. Diuretics should be discontinued if serum sodium is
In the case of recurrent ascites, insertion of a TIPS lower than 120 mmol/l.
should be considered. In experienced centres the
technical success rate is usually high, at about 95%
[65]. Control of ascites is achieved in 8090%, with Spontaneous bacterial peritonitis (SBP)
complete resolution in 75%. TIPS is now considered As mentioned above, SBP is defined as 250
more effective than large volume paracentesis for the neutrophil cells/ml. Culture from ascitic fluid often
control of ascites [6668]. A major problem with discloses bacterial species, such as Escherichia coli and
insertion of TIPS is the relatively high frequency of Streptococcus [44]. Antibiotic treatment of SBP sig-
hepatic encephalopathy, and, although patients often
Scand J Gastroenterol Downloaded from informahealthcare.com by HINARI on 02/13/11
supported, especially in the presence of simulta- [19] Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A,
Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma
neous infections.
and ascitic fluid in patients with cirrhosis. J Hepatol 2001;34: / /
5360.
[20] Moore KP, Aithal GP. Guidelines on the management of
References ascites in cirrhosis. Gut 2006;55 Suppl 6:vi1vi12. / /
disease. Malden: Blackwell; 2005. pp 26070. [28] Henriksen JH, Møller S. Hemodynamics, distribution of
[7] Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in blood volume, and kinetics of vasoactive substances in
cirrhosis. In: Epstein M, editor. The kidney in liver disease.
For personal use only.
[8] Arroyo V, Terra C, Gines P. Advances in the pathogenesis Philadelphia: Hanley and Belfus; 1996. pp 24158.
and treatment of type-1 and type-2 hepatorenal syndrome. J [29] Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver
Hepatol 2007;46:93546.
/ /
2001;21:16174.
/ /
hepatorenal syndrome: altered haemodynamics and neuro- [32] Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker
humoral systems. In: Gerbes AL, Beuers U, Jungst D, U. High arterial compliance in cirrhosis is related to elevated
Pape G, Sackmann M, Sauerbruch T, editors. Hepatology circulating calcitonin gene-related peptide (CGRP) and low
2000. Falk symposium 117. Dordrecht: Kluwer Academic adrenaline, but not to activated vasoconstrictor systems. Gut
Publishers; 2001. pp 185203. 2001;49:1128.
/ /
[12] Schrier RW. Decreased effective blood volume in edematous [33] La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P,
disorders: what does this mean? J Am Soc Nephrol 2007;18: / /
Garcia-Pagan JC, et al. Mineralocorticoid escape in patients
202831. with compensated cirrhosis and portal hypertension. Gastro-
[13] Kravetz D, Bildozola M, Argonz J, Romero G, Korula J, enterology 1992;102:21149.
/ /
Munoz A, et al. Patients with ascites have higher variceal [34] Bernardi M, Li BS, Arienti V, de Collibus C, Scialpi C,
pressure and wall tension than patients without ascites. Am J Boriani L, et al. Systemic and regional hemodynamics in pre-
Gastroenterol 2000;95:17705. / /
ascitic cirrhosis: effects of posture. J Hepatol 2003;39:5028. / /
[14] Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver [35] Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary
Dis 2008;28:25969.
/ /
sodium balance in patients with cirrhosis: relationship to
[15] Garcia-Pagan JC, Hernandez-Guerra M, Bosch J. Extra- quantitative parameters of liver function. Hepatology 1997; /
[17] Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of [37] Angeli P, Wong F, Watson H, Gines P. Hyponatremia in
chronic liver diseases: from the patient to the molecule. cirrhosis: results of a patient population survey. Hepatology
Hepatology 2006;43:S12131. / /
2006;44:153542.
/ /
[18] Møller S, Henriksen JH. The systemic circulation in [38] Bernardi M, Matco CD, Trevisani F, Collibus CD, Fornalé
cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, L, Baraldini M, et al. The hemodynamic status of preascitic
editors. Ascites and renal dysfunction in liver disease. cirrhosis: an evaluation under steady-state conditions and
Malden: Blackwell; 2005. pp 13955. after postural change. Hepatology 1992;16:3416. / /
910 S. Møller et al.
[39] Sansoe G, Ferrari A, Baraldi E, Castellana CN, De Santis starch versus albumin as a plasma expander in cirrhotic
MC, Manenti F. Renal distal tubular handling of sodium in patients with tense ascites treated with paracentesis. Eur J
central fluid volume homoeostasis in preascitic cirrhosis. Gut Gastroenterol Hepatol 1998;10:510. / /
1999;45:7505.
/ /
A, et al. Patterns of regional sympathetic nerve traffic in [58] Gines A, Fernandez-Esparrach G, Monescillo A, Vila C,
preascitic and ascitic cirrhosis. Hepatology 2001;34:11138. / /
disease. Malden: Blackwell Publishing; 2005. Pp 4354. [59] Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP,
[43] Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, Durand F, Chaput JC, et al. Comparison of outcome in
prevention and treatment of the hepatorenal syndrome in patients with cirrhosis and ascites following treatment with
cirrhosis. A consensus workshop of the International Ascites albumin or a synthetic colloid: a randomised controlled pilot
Club. Gut 2007;56:13108. / /
[44] Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and [60] Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione
multiorgan failure in cirrhosis. Semin Liver Dis 2008;28: F, Bernard B, et al. Comparison of the effect of terlipressin
Scand J Gastroenterol Downloaded from informahealthcare.com by HINARI on 02/13/11
/ /
patients with malignancy-related ascites. Scand J Gastro- [61] Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A,
enterol 1990;25:2516./ /
9339.
of paracentesis-induced circulatory dysfunction in cirrhotics:
[48] Gines P, Cardenas A. The management of ascites and
a randomized pilot study. Am J Gastroenterol 2008;103:
hyponatremia in cirrhosis. Semin Liver Dis 2008;28:4358.
/ /
/ /
1399405.
[49] Fernandez-Esparrach G, Guevara M, Sort P, Pardo A,
[64] Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M,
Jimenez W, Gines P, et al. Diuretic requirements after
Rabe C, et al. Prevention of paracentesis-induced circulatory
therapeutic paracentesis in non-azotemic patients with
cirrhosis. A randomized double-blind trial of spironolactone dysfunction: midodrine vs albumin. A randomized pilot
versus placebo. J Hepatol 1997;26:61420. / /
study. Liver Int 2008;28:101925.
/ /
[50] Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, [65] D’amico G, Luca A, Morabito A, Miraglia R, D’Amico M.
Quinones A, et al. Abdominal decompression plays a major Uncovered transjugular intrahepatic portosystemic shunt for
role in early postparacentesis haemodynamic changes in refractory ascites: a meta-analysis. Gastroenterology 2005; /
[51] Pozzi M, Ratti L, Redaelli E, Guidi C, Mancia G. [66] Rössle M, Ochs A, Gulberg V, Siegerstetter V, Holl J,
Cardiovascular abnormalities in special conditions of ad- Deibert P, et al. A comparison of paracentesis and transju-
vanced cirrhosis. The circulatory adaptative changes to gular intrahepatic portosystemic shunting in patients with
specific therapeutic procedures for the management of ascites. N Engl J Med 2000;342:17017. / /
[53] Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, [68] Salerno F, Camma C, Enea M, Rossle M, Wong F.
Torras X, et al. Randomized trial comparing albumin and Transjugular intrahepatic portosystemic shunt for refractory
saline in the prevention of paracentesis-induced circulatory ascites: a meta-analysis of individual patient data. Gastro-
dysfunction in cirrhotic patients with ascites. Hepatology enterology 2007;133:82534.
/ /
2003;37:114753.
/ /
[69] Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus
[54] Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. paracentesis for cirrhotic patients with refractory ascites.
Randomized comparative study of hemaccel vs. albumin Cochrane Database Syst Rev 2006;CD004889.
infusion after total paracentesis in cirrhotic patients with [70] Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G,
refractory ascites. Hepatology 1991;13:70713. / /
Chabbert V, Cortez C, et al. Improved clinical outcome
[55] Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, using polytetrafluoroethylene-coated stents for TIPS: results
Podesta A, et al. Paracentesis with Dextran 70 vs. paracent- of a randomized study. Gastroenterology 2004;126:46975. / /
esis with albumin in cirrhosis with tense ascites. Results of a [71] Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment
randomized study. J Hepatol 1992;14:3106. / /
of hepatorenal syndrome. Semin Liver Dis 2008;28:8195. / /
[56] Altman C, Bernard B, Roulot D, Vitte RL, Ink O. [72] Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L,
Randomized comparative multicenter study of hydroxyethyl Guevara M, Ars E, et al. Aquaporin-1 and aquaporin-2
Treatment of ascites 911
urinary excretion in cirrhosis: relationship with ascites and [76] Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-
hepatorenal syndrome. Hepatology 2006;44:155563.
/ /